Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
April 1, 2002Fundamental and Clinical Pharmacology

In vivo measurement of QT prolongation, dispersion and arrhythmogenesis: application to the preclinical cardiovascular safety pharmacology of a new chemical entity

View Full Paper
Ask AI
Bookmark
Share

Population

Experimental animal models used for cardiovascular safety pharmacology

Design

Review

Authors

FCFred De ClerckAWA. Van de WaterJDJan D'Aubioul

Discussion

Loading...

Member takes

Overview

Reinforces in vivo animal models for QT safety assessment; leaves open optimal translation to clinical risk.

Structured PICO

P
Population
Experimental animal models (anaesthetized guinea-pigs, anaesthetized and awake dogs, anaesthetized methoxamine-challenged rabbits) used for cardiovascular safety pharmacology
I
Intervention
In vivo testing of new chemical entities (NCEs) for cardiac electrophysiology and arrhythmogenesis

In vivo experimental animal models are essential for the comprehensive cardiovascular safety pharmacology assessment of new chemical entities, particularly regarding QT prolongation and arrhythmogenic risk.

Cite This Study

Clerck et al. (2002) studied this question.

synapsesocial.com/papers/6a7588a0756843cacbb20fc1https://doi.org/10.1046/j.1472-8206.2002.00081.x
View Full Paper
Ask AI
Bookmark
Share